Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome

Biology of Reproduction

Volumn 87, Issue 2, 2012, Pages

  Zhai, Jun ^a   Liu, Chun Xi ^b   Tian, Zuo Rong ^b   Jiang, Qiu Hui ^b   Sun, Ying Pu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU PEOPLE S HOSPITAL   (China)

Author keywords

Glucose transporter 4; Insulin resistance; Metformin; Polycystic ovary syndrome

Indexed keywords

ESTRADIOL; FOLLITROPIN; GLUCOSE TRANSPORTER 4; LUTEINIZING HORMONE; MESSENGER RNA; METFORMIN; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIET RESTRICTION; ENDOMETRIUM; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN BLOOD LEVEL; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADULT; BODY MASS INDEX; CASE-CONTROL STUDIES; ENDOMETRIUM; FEMALE; GLUCOSE TRANSPORTER TYPE 4; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME; RNA, MESSENGER; YOUNG ADULT;

EID: 84869479453     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.112.099788     Document Type: Article

References (30)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745-2749.
2. Costello M, Eden JA. A systemic review of the reproductive systerm effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003; 79:1-13.
3. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
4. Morales AJ, Laughlin GA. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996; 81:2854-2864.
5. Dunaif A, Segal, KR, Shelley, DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinstic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41:1257-1266.
6. Maison P, Byrne CD, Hales CN, Day NE, Wareham NJ. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 2001; 24:1758-1763.
7. Imani B, Eijkemans MJ, Velde ER, Habbema JD, Fauser BC. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligomenorrheic infertility. Fertil Steril 2002; 77:91-97.
8. Wang W, Shen HM, Li XD, Hao GM, Cui N, Xu SX. Expression and significance of glucose transporter 4 in endometrium of patients with polycystic ovarian syndrome after inducing ovulation. Maternal and Child Health Care of China 2009; 77:91-97.
9. Mioni R, Chiarelli S, Xamin N, Zuliani L, Granzotto M, Mozzanega B, Maffei P, Martini C, Blandamura S, Sicolo N, Vettor R. Evidence for the presence of glucose transporter 4 in the endometrium and its regulation in polycystic ovary syndrome patients. J Clin Endocrinol Metab 2004; 89: 4089-4096.
10. Jensterle M, Janez A, Mlinar1 B, Marc J, Prezelj J, Pfeifer M. Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. Eur J Endocrinol 2008; 158:793-801.
11. Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003; 361:1894-1901.
12. Lord JM, Flinght IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327:951-953.
13. The Rotterdam ESHRE/ASRM-Sponsored PCOS Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19-25.
14. Ge QS. Clinical Reproductive Endocrinology. Beijing: Science and Technology Literature Publishing House; 2001:379-381.
15. Xing XY, Yang WY, Yang ZJ. The diagnostic significance of homeostasis model assessment of insulin resistance in metabolic syndrome among subjects with different glucose tolerance. Chin J Diabetes 2004; 12: 182-186.
16. Xie TN, Yue Y. Advance research of insulin resistance in polycystic ovary syndrome. J Jilin University (Medical Edition) 2010; 36:424-428.
17. Kriplani A, Agarwal N. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. J Reprod Med 2004; 49: 361-367.
18. Hahn S, Quadbeck B, Elsenbruch S, Gärtner R, Finke R, Mann K, Janssen OE. Metformin, an efficacious drug in the treatment of polycystic ovary syndrome. Dtsch Med Wochenschr 2004; 129:1059-1064.
19. Diamanti-Kandarakis E, Christakou CD, Kandaraki E. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 2010; 162:193-212.
20. Zhang ZW. Research advances in the physiological role of glucose transporter 4 in cells. Journal of Practical Diagnosis and Therapy 2005; 19: 191-193.
21. Sheets EE, Tsibris JCM, Cook NI, Virgin SD, DeMay RM, Spellacy WN. In vitro binding of insulin and epidermal growth factor to human endometrium and endocervix. Am J Obstet Gynecol 1985; 153:60-65.
22. Truchan B, Taylor P, Goren HJ, Lederis K, Hollenberg MD, Okabe T. Basal, oxytocin and insulin-stimulated glucose oxidation in human endometrium. Can J Physiol Pharmacol 1987; 65:323-327.
23. Shepherd PR, Kahn BB. Glucose transporters and insulin actionimplication for insulin resistance and diabetes mellitus. N Engl J Med 1999; 341:248-257.
24. Mueckler M. Insulin resistance and the disruption of GLUT4 trafficking in skeletal muscle. J Clin Invest 2001; 107:1211-1213.
25. Furuta M, Yano Y, Gabazza EC, Araki-Sasaki R, Tanaka T, Katsuki A, Hori Y, Nakatani K, Sumida Y, Adachi Y. Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus. Diabetes Res Clin Pract 2002; 56:159-171.
26. Fornes R, Ormazabal P, Rosas C, Gabler F, Vantman D, Romero C, Vega M. Changes in the expression of insulin signaling pathway molecules in endometria from polycystic ovary syndrome women with or without hyperinsulinemia. Mol Med 2010; 16:129-136.
27. Sato K, Iemitsu M, Aizawa K, Ajisaka R. Testosterone and DHEA activate the glucose metabolism-related signaling pathway in skeletal muscle. Am J Physiol Endocrinol Metab 2008; 294:E961-E968.
28. Rosenfield RL. Polycystic ovary syndrome and insulin-resistant hyperinsulinemia. J Am Acad Dermatol 2001; 45(SUPPL 3):S95-S102.
29. Rosenbaum D, Haber RS, Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol 1993; 264(2 Pt-1):E197-E202.
30. Detaile D, Wiernsperger N, Devos P. Metformin interaction with insulinregulated glucose uptake, using the xenopus laevis oocyte model expressing the mammalian GLUT4. Eur J Pharmacol 1999; 377:127-136.